An interventional study of Therapeutic Lens Coating and Sham Lens Coating in Migraine Disorders and Photophobia, sponsored by Bradley Katz. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-31.
Sponsored by Bradley Katz · Not applicable, Interventional, and Treatment
Approximately 9% of men and 18% of women suffer from migraine headaches. Almost all migraine sufferers report light sensitivity during a headache. Some people with migraine report that light can trigger their migraines and some people with migraine are light sensitive all of the time. The investigators have recently determined that certain colors of light are more likely to trigger migraines than other colors. In this study the investigators want to know if people who wear glasses that block these colors of light will have fewer migraine headaches.
Exclusion Criteria:
Subjects will wear a therapeutic lens coating for 2 weeks
Other: Therapeutic Lens Coating · Other: Sham Lens Coating
Subjects will wear a sham lens coating for 2 weeks
Other: Therapeutic Lens Coating · Other: Sham Lens Coating
Subjects will wear a therapeutic lens coating for 2 weeks.
Each subject will wear a sham lens coating for 2 weeks.
HIT-6
Primary outcome measure is improvement in HIT-6 while wearing therapeutic lenses compared to baseline. The HIT-6 is the Headache Impact Test, a trademarked and copyrighted test (2001 QualityMetric, Inc. and GlaxoSmithKline Group of Companies)
Time frame: 10 weeks
Headache frequency and severity
Secondary outcome is reduction in headache frequency and severity as assessed by headache diaries.
Time frame: 10 weeks
Photophobia
Tertiary outcome is reduction in photophobia as assessed by a photophobia questionnaire.
Time frame: 10 weeks
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.